Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06233903 | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | withdrawn | Phase 2 | 0 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)INDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 17, 2025 |
| clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06308575 | A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 10, 2025 | clinicaltrials |
| NCT06135545 | Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block | withdrawn | N/A | 0 | Shiyou WeiOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | withdrawn | Phase 4 | 0 | Corewell Health EastOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05145569 | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Jan 1, 2025 | clinicaltrials |
| NCT05456165 | Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer | withdrawn | Phase 2 | 0 | Gritstone bio, Inc.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05861336 | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer(OVERPASS) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Dec 20, 2024 | clinicaltrials |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | withdrawn | Early Phase 1 | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT04093557 | Improving Outpatient Colonoscopy Bowel Prep With the Orton Score | withdrawn | N/A | 0 | University of VirginiaOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05094544 | Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC(POIMS) | withdrawn | N/A | 0 | University of Kansas Medical CenterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT01350180 | Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis | withdrawn | — | 0 | Dr. Tamim NiaziOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02347839 | NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.(NEGOTIATE) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02428764 | Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | withdrawn | — | 0 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Dec 10, 2024 | clinicaltrials |
| NCT03164694 | APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC(APPEAL) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06227897 | Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).(AERESA) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer(Breast50) | withdrawn | Early Phase 1 | 0 | University of VirginiaOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT03802747 | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | withdrawn | Phase 1 | 0 | University of Colorado, DenverOTHER | 0 | Dec 9, 2024 | clinicaltrials |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | withdrawn | Phase 2 | 0 | MedPacto, Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722885 | Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System(SBRT_LOV) | withdrawn | — | 0 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT02883361 | Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors(MI for AIs) | withdrawn | Phase 2 / Phase 3 | 0 | University of CalgaryOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03939585 | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT | withdrawn | Phase 1 | 0 | Leland MethenyOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02699229 | Non-linear Multimodal Microendoscopy for Lung Cancer Pathology | withdrawn | — | 0 | University Health Network, TorontoOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Tel Aviv Medical CenterOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT06463184 | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Dec 4, 2024 | clinicaltrials |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Nov 29, 2024 | clinicaltrials |
| NCT03622528 | Quantitative Lung Cancer Screening | withdrawn | — | 0 | Jessica SierenOTHER | 0 | Nov 27, 2024 | clinicaltrials |
| NCT04160182 | Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04232319 | Feasibility and Effectiveness of a Sleep Hygiene Education Program for Sleep Issues in Breast Cancer Survivors | withdrawn | N/A | 0 | University of Toledo Health Science CampusOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04272294 | Functional and Molecular Characterization of Treatment Response in Tumors in the Oral Cavity Using Optical Spectroscopy | withdrawn | N/A | 0 | University of ArkansasOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04808115 | IIT PH1 KDS-1001 in Patients With CML | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT05427344 | Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients | withdrawn | N/A | 0 | Tel Aviv UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05418387 | A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona | withdrawn | N/A | 0 | University of ArizonaOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06207786 | Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42) | withdrawn | Phase 4 | 0 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Nov 21, 2024 | clinicaltrials |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06068153 | AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC(AMBER) | withdrawn | Phase 2 | 0 | ETOP IBCSG Partners FoundationNETWORK | 4 | Nov 20, 2024 | clinicaltrials |
| NCT04007549 | Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.(IBMC) | withdrawn | N/A | 0 | Institut BergoniéOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05817994 | Endoscopic Ultrasound Guided Liver Biopsy and Portal Pressure Registry(REGAL) | withdrawn | — | 0 | Sheikh Shakhbout Medical CityOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Kathleen DorritieOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT02588846 | Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM(KOALA) | withdrawn | N/A | 0 | Royal North Shore HospitalOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Nov 18, 2024 | clinicaltrials |
| NCT03228043 | Apatinib for Resectable Colorectal Cancer | withdrawn | N/A | 0 | Nanchong Central HospitalOTHER_GOV | 1 | Nov 14, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jan 21, 2025source: clinicaltrials